CTLA-4-TF tag mRNA-LNP

CTLA-4 (cytotoxic T lymphocyte-associated protein 4), also known as CD152, is a protein receptor of the immunoglobulin superfamily. It is encoded by the CTLA4 gene and is constitutively expressed in regulatory T cells. The protein contains an extracellular V domain, a transmembrane domain and a cytoplasmic tail. Alternative transcriptional splice variants encoding different isoforms have been characterized. The membrane-bound isoform acts as a homodimer interconnected by disulfide bonds, while the soluble isoform acts as a monomer. The function of CTLA-4 is thought to be the recruitment of phosphatases to the T cell receptor (TCR). CTLA-4 also functions to capture and remove CD80 and CD86 from antigen-presenting cell membranes, making them unable to trigger CD2. As an immune checkpoint, CTLA-4 has attracted great interest in immunotherapy of cancer patients. Ipilimumab, an antagonistic antibody against CTLA, is the first immune checkpoint blockade therapy approved by the FDA for the treatment of cancer.
This product is designed as a tool for the delivery and expression of human TF tagged CTLA-4 mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of CTLA-4-TF mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The CTLA-4-TF fusion protein is approximately 23 kD, consisting of mature CTLA-4 (188 amino acids) and a C-terminal TF tag (15 amino acids). The mature peptide sequence of CTLA-4 is 36-223 of 223 amino acids, GenPept accession number is NP_005205.